rabi
viru
remain
import
burden
diseas
claim
estim
live
year
mainli
children
huge
econom
societ
cost
postexposur
prophylaxi
pep
highli
effect
howev
patient
present
neurolog
symptom
casefat
ratio
extrem
high
last
decad
sever
attempt
identifi
potent
effect
antivir
made
demonstr
improv
clinic
sign
anim
studi
none
trial
human
show
signific
efficaci
explor
novel
opportun
identifi
potent
antirabi
molecul
particular
import
progress
made
antivir
mononegaviral
paramyxovirus
filovirus
impetu
test
optim
molecul
toward
antirabi
viru
therapi
effect
rabi
antivir
therapeut
use
need
molecul
dose
cerebrospin
fluid
rapidli
potent
block
ongo
viru
replic
stop
spread
viru
antivir
prophylact
use
also
envisag
abl
prevent
infect
peripher
nerv
cell
potenti
replac
current
antirabi
immunoglobulin
use
pep
rabi
viru
remain
import
burden
diseas
claim
estim
live
year
mainli
children
huge
econom
societ
cost
postexposur
prophylaxi
pep
highli
effect
howev
patient
present
neurolog
symptom
casefat
ratio
extrem
high
last
decad
sever
attempt
identifi
potent
effect
antivir
made
demonstr
improv
clinic
sign
anim
studi
none
trial
human
show
signific
efficaci
explor
novel
opportun
identifi
potent
antirabi
molecul
particular
import
progress
made
antivir
mononegaviral
paramyxovirus
filovirus
impetu
test
optim
molecul
toward
antirabi
viru
therapi
effect
rabi
antivir
therapeut
use
need
molecul
dose
cerebrospin
fluid
rapidli
potent
block
ongo
viru
replic
stop
spread
viru
antivir
prophylact
use
also
envisag
abl
prevent
infect
peripher
nerv
cell
potenti
replac
current
antirabi
immunoglobulin
use
pep
rabi
viru
infect
caus
encephalomyel
human
nearli
case
fatal
rate
current
strategi
postexposur
prophylaxi
treatment
pep
exampl
dog
bite
highli
effect
involv
vaccin
togeth
infiltr
wound
antirabi
immunoglobulin
rig
year
ten
thousand
peopl
mani
children
succumb
rabi
societ
cost
worldwid
estim
excess
us
billion
includ
us
billion
spent
postexposur
prophylaxi
clinic
rabi
develop
mainli
peopl
receiv
pep
patient
progress
virtual
alway
toward
coma
death
rare
survivor
often
infect
less
virul
batderiv
lyssavirus
high
titer
antibodi
serum
cerebrospin
fluid
csf
fatal
rabi
case
minor
patient
antibodi
serum
none
neutral
antibodi
csf
indic
survivor
neutral
antibodi
reach
csf
effect
halt
elimin
viru
replic
therefor
block
rabi
viru
replic
central
nervou
system
cn
could
effect
treatment
pathogenesi
rabi
remain
subject
studi
advers
detriment
host
respons
expect
play
role
well
success
treatment
may
requir
combin
antivir
inflammatori
drug
effect
antivir
could
also
use
pep
replac
use
rig
short
suppli
throughout
world
current
effort
challeng
discoveri
develop
rabi
antivir
recent
review
thoroughli
briefli
updat
work
antivir
explor
effort
need
find
potent
antirabi
molecul
ribavirin
interferonalpha
broadspectrum
antivir
signific
vitro
activ
rabi
vivo
experi
treatment
sever
human
patient
rabi
infect
show
benefici
activ
two
fda
approv
drug
vitro
antirabi
activ
nmethyldaspart
nmda
receptor
antagonist
ketamin
amantadin
last
one
also
approv
treatment
influenza
ketamin
show
effect
rabi
infect
anim
studi
amantadin
efficaci
anim
could
demonstr
combin
ketamin
amantadin
explor
patient
togeth
treatment
intervent
socal
milwauke
protocol
protocol
high
coverag
media
first
patient
treat
recov
repeat
consid
ineffect
anoth
recent
approv
drug
explor
rabi
infect
favipiravir
broad
spectrum
antivir
intracellular
host
enzym
convert
favipiravir
activ
form
mechan
action
remain
topic
discuss
mimic
purin
nucleotid
analog
select
inhibit
rnadepend
rna
polymeras
rdrp
caus
lethal
mutagenesi
upon
incorpor
viral
rna
favipiravir
current
approv
treatment
influenza
japan
clinic
develop
unit
state
recent
yamada
et
al
show
favipiravir
also
antivir
activ
rabi
viru
vivo
experi
show
condit
earli
start
treatment
improv
clinic
sign
surviv
rate
mice
infect
intramuscularli
start
favipiravir
treatment
delay
day
signific
protect
effect
observ
indic
favipiravir
might
ineffect
virus
locat
within
nervou
system
may
effect
neuroinvas
addit
repurpos
exist
drug
novel
antivir
strategi
explor
rabi
review
extens
recent
paper
appolinario
jackson
well
follow
highlight
addit
strategi
nucleosid
select
inhibit
polymeras
virus
approv
treatment
herp
viru
human
immunodefici
viru
hiv
hepat
c
viru
hcv
hepat
b
viru
hbv
discoveri
nucleosid
specif
inhibit
neg
strand
rna
viru
polymeras
challeng
howev
recent
year
sever
nucleosid
activ
respiratori
syncyti
viru
rsv
ebola
viru
discov
discuss
excel
candid
explor
rabi
viru
nucleosid
rsv
enter
clinic
trial
esterprodrug
cytidin
nucleosid
analog
biochem
studi
reveal
triphosph
potent
select
inhibitor
rsv
rnadepend
rna
polymeras
activ
k
mm
via
classic
chain
termin
mechan
vitro
experi
also
show
activ
parainfluenza
viru
vesicular
stomat
viru
vsv
ec
vsv
report
mm
less
activ
rsv
still
good
select
cc
mm
activ
detect
neg
strand
rna
virus
beyond
paramyxoand
rhabdovirida
famili
activ
note
test
posit
strand
rna
virus
indic
prodrug
need
metabolis
becom
activ
particular
phosphoryl
nucleosidetriphosph
step
cell
type
depend
explor
neuron
case
rabi
anoth
recent
seri
antirsv
nucleosid
fnucleosid
yet
character
anim
studi
activ
neg
strand
rna
virus
report
given
activ
rsv
may
worthwhil
explor
molecul
antirabi
viru
activ
nucleosid
broadspectrum
activ
picorna
flavi
orthomyxo
paramyxoand
filovirus
vitro
unfortun
activ
rhabdovirus
vsv
rabi
viru
yet
report
shown
efficaci
sever
viru
infect
anim
model
current
develop
treatment
ebola
viru
diseas
given
broadspectrum
good
efficaci
sever
anim
model
viru
diseas
includ
infect
neg
strand
virus
molecul
candid
explor
rabi
infect
monophosph
prodrug
discov
recent
antiebola
viru
screen
campaign
broadspectrum
antivir
activ
sever
pathogen
rna
virus
includ
filovirus
arenavirus
paramyxovirus
coronavirus
rhesu
monkey
model
ebola
viru
diseas
show
good
efficaci
even
treatment
initi
three
day
infect
given
broadspectrum
activ
filovirus
paramyxovirus
nucleotideprodrug
may
also
inhibit
rhabdovirus
includ
rabi
uniqu
approach
investig
potenti
rabi
viru
antivir
strategi
studi
peptid
disrupt
interact
viral
ribonucleoprotein
complex
rnp
land
pprotein
rabi
rnp
built
around
nprotein
oligomer
form
helix
around
viral
rna
wrap
rnp
templat
transcript
replic
rdrp
l
protein
viral
rna
synthesi
mediat
viral
phospho
p
protein
multifunct
protein
interact
l
n
pprotein
allow
effici
specif
recognit
rnp
templat
rdrp
subsequ
rna
polymer
way
p
permit
continu
contact
rdrp
rnp
rdrp
progress
ntermin
domain
pprotein
interact
nand
lprotein
chosen
tool
explor
novel
antivir
strategi
peptid
deriv
domain
shown
interact
directli
nand
lprotein
abl
block
rabi
viru
replic
cell
cultur
interest
note
correspond
ppeptid
previous
also
shown
inhibit
replic
rsv
nipah
viru
detail
character
bind
mode
peptid
n
protein
could
therefor
lead
gener
principl
inhibit
rhabodovirus
paramyxovirus
antivir
rabi
expect
major
impact
could
block
elimin
viral
replic
patient
show
first
neurolog
symptom
diseas
addit
effect
antivir
might
capac
replac
use
rig
avail
limit
today
none
antivir
proven
vitro
andor
vivo
activ
test
human
demonstr
good
efficaci
growth
knowledg
recent
year
regard
antivir
relat
virus
paramyxovirus
filovirus
stimulu
test
optim
toward
antirabi
viru
therapi
mani
challeng
lay
ahead
molecul
must
activ
cn
cope
highli
aggress
viral
diseas
given
success
antivir
aggress
viral
infect
herp
hiv
hcv
believ
similarli
resolut
effort
must
undertaken
order
develop
effect
antirabi
therapi
work
support
european
union
seventh
framework
program
asklepio
grant
agreement
grant
funder
role
studi
design
data
collect
interpret
decis
submit
work
public
